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Abstract 
A simple, specific and stability indicating reversed phase high performance 
liquid chromatographic method was developed for the simultaneous 
determination of paracetamol and lornoxicam in tablet dosage form. A Brownlee 
C-18, 5 μm column having 250×4.6 mm i.d. in isocratic mode, with mobile 
phase containing 0.05 M potassium dihydrogen phosphate:methanol (40:60, 
v/v) was used. The flow rate was 1.0 ml/min and effluents were monitored at 
266 nm. The retention times of paracetamol and lornoxicam were 2.7 min and 
5.1 min, respectively. The linearity for paracetamol and lornoxicam were in the 
range of 5–200 µg/ml and 0.08–20 µg/ml, respectively. Paracetamol and 
lornoxicam stock solutions were subjected to acid and alkali hydrolysis, 
chemical oxidation and dry heat degradation. The proposed method was 
validated and successfully applied to the estimation of paracetamol and 
lornoxicam in combined tablet dosage form. 
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Introduction 
Lornoxicam (LRN) is chemically 6-chloro-4-hydroxy-2-methyl-N-(pyridin-2-yl)-2H-
thieno[2,3-e][1,2]thiazine-3-carboxamide 1,1-dioxide.  Lornoxicam is non steroidal anti-
inflammatory drug and it inhibits prostaglandin biosynthesis by blocking the enzyme cyclo-
oxygenase. Unlike some NSAIDs, Lornoxicam do not inhibit 5-lipoxygenase activity and 
thus do not inhibit leukotriene synthesis [1]. Paracetamol (PCM) is chemically 4-hydroxy-
acetanilide. PCM is a weak inhibitor of peripheral cyclooxygenase and its analgesic effects 
may arise from inhibition of prostanoid synthesis in the CNS. The antipyretic effects of 
PCM are due to its action at the level of the hypothalamus to reduce pyrogen-initiated 
alterations in body temperature by inhibiting prostaglandin synthesis [2,  3]. The 
combination dosage form of paracetamol and lornoxicam is available in the market and it 
is indicated in the treatment of rheumatism and in reduction of post operative pain. 
Literature survey revealed that liquid chromatographic (LC) [4, 5], LC-electrospray tendem 
mass spectrometry [6, 7] methods have been reported for the estimation of lornoxicam. 
Paracetamol is official in Indian Pharmacopoeia and British Pharmacopoeia. Different LC 
methods have been reported for the estimation of PCM [3, 8]. Literature survey revealed 
no method reported for the estimation of PCM and LRN in combined dosage form. Present 
study involves development of a stability liquid chromatographic method for the estimation 
of LRN and PCM in combination dosage form. 
Results and Discussion  
Optimization of mobile phase: 
Optimization of mobile phase was performed based on resolution of the drugs and 
degradation products, asymmetric factor and theoretical plates obtained for LRN and 
PCM. The mobile phase consisting of 0.05 M potassium dihydrogen phosphate: methanol 
(40:60, v/v) was selected which gave sharp, well-resolved peaks for LRN and PCM (fig. 1).  
 
Fig. 1.   Liquid chromatogram of PCM and LRN 
The retention times for PCM and LRN were 2.7 and 5.1 min, respectively. The asymmetric 
factors for LRN and PCM were 1.2 and 1.4, respectively. UV overlaid spectra of LRN and 
PCM showed that all the drugs absorbed appreciably at 266 nm, so the same was 
selected as the detection wavelength during the studies.   Stability Indicating LC-Method for Estimation of Paracetamol and Lornoxicam in Combined …  115 
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Validation: 
The calibration curve was found to be linear over the range of 0.08–20 µg/ml for LRN and 
5–200 µg/ml for PCM. The data of regression analysis of the calibration curves are shown 
in table 1.  
Tab. 1.   Regression analysis of the calibration curve for the proposed method 
Parameters LRN  PCM 
Linearity range (µg/ml)  0.08–20  5–200 
Slope 61529  61190 
Standard deviation of slope  45.288  47.69 
Intercept 1097  809.6 
Standard deviation of intercept  285.89  298.038 
Correlation coefficient   0.9980  0.9950 
 
The accuracy of the method was determined by calculating recoveries of LRN and PCM by 
method of standard additions. The recoveries obtained were 97.28–100.34% for LRN and 
98.24–100.07% for PCM, respectively. The high values indicate that the method is 
accurate. Instrument precision was determined by performing injection repeatability test 
and the RSD values for LRN and PCM were found to be 0.61% and 0.02%, respectively. 
The intra-day and inter-day precision studies were carried out. For the intra-day study RSD 
values were found to be 0.07–0.88% for LRN and 0.05–1.12% for PCM and for inter-day 
precision study RSD values were found to be 0.09–1.95% for LRN and 0.07–1.45% for 
PCM, respectively. The low RSD values indicate that the method is precise. The detection 
limits for LRN and PCM were 0.007 µg/ml and 0.54 µg/ml, respectively, while quantitation 
limits were 0.02  µg/ml and 1.59  µg/ml, respectively. The above data shows that a 
nanogram quantity of both the drugs can be accurately and precisely determined. The 
validation parameters are summarized in table 2 and the system suitability test parameters 
are shown in table 3.  
Tab. 2.   Summary of validation parameters  
Parameters LRN  PCM 
Detection limit (µg/ml)  0.007  0.54 
Quantitation limit (µg/ml) 0.02  1.59 
Accuracy(%) 97.28–100.34%  98.24–100.07% 
Precision (RSD
a,%)    
 Intra-day  precision  (n=3) 0.07–0.88%  0.05–0.12% 
 Inter-day  precision  (n=3) 0.09–1.95%  0.07–1.45% 
Instrument precision (RSD
a) 0.61%  0.02% 
Robustness 97.12–100.56%  98.45–99.18% 
a RSD is relative standard deviation and ‘n’ is number of determinations 
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Tab. 3. System suitability test parameters for the proposed method 
System suitability parameters  LRN  PCM 
Retention time  5.1 min  2.7 min 
Theoratical plates/ meter  5417  4349 
Assymetric factor  1.2  1.4 
Resolution 11  – 
 
Robustness of the method was studied by changing the flow rate of the mobile phase from 
1ml/min to 0.8 ml/min and 1.2 ml/min. Using 1.2 ml/min flow rate, retention time for LRN 
and PCM were observed to be 4.9 and 2.6 min, respectively and with 0.8 ml/min flow rate, 
retention times for LRN and PCM were observed to be 5.4 and 2.9 min, respectively 
without affecting the resolution of the drugs. When mobile phase composition was 
changed to 0.05 M potassium dihydrogen phosphate: methanol (35:65, v/v) by increasing 
percentage of methanol, the retention time for LRN and PCM were observed to be 4.9 and 
2.7 min, respectively. The solution stability study revealed that LRN and PCM solutions 
were stable for 24 h with out detectable degradation and the percentage recovery of both 
the drugs were found to be more than 97%. 
Forced degradation study: 
Forced degradation study was carried out by subjecting both the drugs to acid and alkali 
hydrolysis, chemical oxidation and dry heat degradation conditions. The chromatograms of 
base degraded sample showed degradation product peaks at retention time (RT) 3.4, 3.7, 
5.5 and 6.9 min for LRN and PCM was found to be stable to base degradation (fig. 2, 3).  
 
Fig. 2.   Chromatogram of base treated LRN   Stability Indicating LC-Method for Estimation of Paracetamol and Lornoxicam in Combined …  117 
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Fig. 3.  Chromatogram of base treated PCM 
The peaks of the degradation products were well resolved from the drug peaks. The 
chromatograms of acid degraded sample showed degradation product peaks at retention 
time (RT) 3.7, 4.7, 5.5 and 8.3 min for LRN and PCM was found to be stable to acid 
degradation (fig. 4, 5).  
 
Fig. 4.   Chromatogram of acid treated LRN 118  D. A. Shah et al.:  
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Fig. 5.   Chromatogram of acid treated PCM 
Both LRN and PCm were found to be stable to both oxidative stress degradation and dry 
heat degradation.  
The degradation study thereby indicated that LRN was stable to dry heat and chemical 
oxidation study while it was susceptible to base and acid hydrolysis. PCM was found to be 
highly stable molecule which do not underwent degradation in the proposed conditions 
(table 4).  
Tab. 4.   Forced degradation study of LRN and PCM for the proposed method. 
Recovery (%)  Retention time of 
degradation products  Condition  Time 
(h) 
PCM LRN PCM  LRN 
Base 1 N NaOH  24  97.56  32.16  –  3.4, 3.7, 5.5  
and 6.9 
Acid 1 N HCl  24  98.24  30.62  –  3.7, 4.7, 5.5  
and 8.3 
3% hydrogen peroxide  24  99.45  97.51  –  – 
Dry heat
b 2  97.92  95.62  –  – 
b Samples were heated at 80 
o for specified period of time. 
 
Analysis of marketed formulation: 
The proposed method was applied to the determination of LRN and PCM in their 
combined dosage form (Tablet A). The results for LRN and PCM were comparable with 
the corresponding labeled amounts (Table 5).  
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Tab. 5.   Assay results of tablet dosage form using proposed method 
Formulation  Labelled 
Amount (mg) % Recovery 
c 
 PCM  LRN  PCM  LRN 
A  500  8  100.01 ± 0.72  98.56 ± 0.37 
c mean value ± standard deviation of three determinations; Tablet 
formulation A is LORNASAFE-PLUS (Mankind Pharmaceutical Ltd., India) 
containing labeled amount of 500 mg paracetamol and 8 mg of lornoxicam. 
 
Experimental 
The liquid chromatographic system of perkin elmer series 200 containing quaternary 
gradient pump, variable wavelength programmable UV/Vis detector and rheodyne injector 
with 20 μl fixed loop was used. A Brownlee C18 column with 250×4.6 mm i.d. and 5 μm 
particle size was used. Analytically pure PCM was procured as gift sample from M/s 
Baroque Pharmaceutical Ltd., (Khambhat, India). LRN was procured as gift sample from 
M/s Zydus Cadila Pvt. Ltd., (Ahmedabad, India). Methanol, water (E. Merck, Mumbai, 
India) were of LC grade, while potassium dihydrogen phosphate (S.D. fine chemicals, 
Mumbai, India) was of analytical grade used for the preparation of mobile phase. Tablet 
formulation A (LORNASAFE-PLUS, Mankind Pharmaceutical Ltd., India) containing 
labeled amount of 8 mg of lornoxicam and 500 mg of paracetamol were purchased from 
local market 
Preparation of mobile phase and stock solution 
Mobile phase was prepared by accurately weighing 6.8 g of potassium dihydrogen 
phosphate and dissolving in 1000 ml of water. Later 400 ml of this solution was mixed with 
600 ml of methanol. The solution was filtered with Whatman filter paper (0.45 µm). The 
solution was sonicated for 15 min for degassing prior to use.  
Stock solutions were prepared by accurately weighing 25 mg each of PCM and LRN and 
transferring to two separate 25 ml volumetric flasks containing 10 ml of methanol. The 
flasks were sonicated for 10 minutes to dissolve the solids. Volumes were made up to the 
mark with methanol, which gave 1000 μg/ml of both the drugs. Aliquots from the stock 
solutions were appropriately diluted with mobile phase to obtain working standards of 100 
μg/ml of each drug.  
Chromatographic conditions 
A reversed phase C18 column (Brownlee) equilibrated with mobile phase comprising of 
methanol: 0.05M potassium dihydrogen phosphate (60:40, v/v) was used. Mobile phase 
flow rate was maintained at 1 ml/ min and eluent were monitored at 266 nm. A 20 μL of 
sample was injected using a fixed loop, and the total run time was 10  min. All the 
chromatographic separations were carried out at controlled room temperature (20–25°C). 
Calibration curves for PCM and LRN 
Appropriate aliquots of PCM working standard solution were taken in different 10 ml 
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same flasks. The volumes were made up to the mark with mobile phase to obtain final 
concentrations of 5, 25, 50, 100, 150 and 200 µg/ml of PCM and 0.08, 0.4, 2, 10, 15 and 
20 µg/ml of LRN, respectively. The solutions were injected using a 20 μL fixed loop system 
and chromatograms were recorded. Calibration curves were constructed by plotting peak 
area versus concentrations of the drug and regression equations were computed for PCM 
and LRN. 
Analysis of Marketed Formulations 
Twenty tablets were weighed accurately and finely powdered. Tablet powder equivalent to 
500mg PCM (and 8 mg of LRN) was taken in 50 ml volumetric flask. A few ml (20 ml) of 
methanol was added to the above flask and the flask was sonicated for 15 minutes. The 
solution was filtered in another 50 ml volumetric flask using Whatman filter paper and 
volume was made up to the mark with the same solvent.  
Appropriate volume of the aliquot was transferred to a 10 ml volumetric flask and the 
volume was made up to the mark with the mobile phase to obtain a solution containing 100 
µg/ml of PCM and 1.6 µg/ml of LRN. The solution was sonicated for 10 min. It was injected 
as per the above chromatographic conditions and peak area was recorded. The 
quantifications were carried out by keeping these values to the straight line equation of 
calibration curve. 
Validation 
The method was validated for accuracy, precision, specificity, detection limit, quantitation 
limit and robustness. The accuracy of the method was determined by calculating 
recoveries of LRN and PCM by method of standard additions. Known amount of LRN (0, 1, 
5, 10 μg/mμl) and PCM (0, 10, 50, 100 μg/ml) were added to a pre quantified sample 
solutions and the amount of PCM and LRN were estimated by measuring the peak area 
and by fitting these values to the straight-line equation of calibration curve. 
The instrument precision was evaluated by injecting the solution containing LRN (2 μg/ml) 
and PCM (100 μg/ml) six times repeatedly and peak area was measured. The results are 
reported in terms of relative standard deviation. The intra-day and inter-day precision study 
of LRN and PCM was carried out by estimating the corresponding responses 6 times on 
the same day and on 3 different days (first, second and third day) for 3 different 
concentrations of LRN (0.08, 2, 20 μg/ml) and PCM (5, 100, 200 μg/ml), and the results 
are reported in terms of relative standard deviation (RSD). The specificity was estimated 
by spiking commonly used excipient (starch, talc and magnesium stearate) into a pre 
weighed quantity of drug. The chromatogram was taken by appropriate dilutions and the 
quantities of drugs were determined.  
The detection limit is defined as the lowest concentration of an analyte that can reliably be 
differentiated from background levels. Limit of quantification of an individual analytical 
procedure is the lowest amount of analyte that can be quantitatively determined with 
suitable precision and accuracy. LOD and LOQ were calculated using following equation 
as per ICH guidelines. LOD = 3.3 ×σ /S and LOQ = 10 ×σ /S, where σ is the standard 
deviation of y-intercepts of regression lines and S is the slope of the calibration curve.    Stability Indicating LC-Method for Estimation of Paracetamol and Lornoxicam in Combined …  121 
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Robustness of the method was studied by deliberately changing the experimental 
conditions like flow rate, percentage of organic phase and also by observing the stability of 
the sample solution at 25 ± 2° for 24 h. The sample solution was assayed at every 6 h 
interval up to 24 h. 
Forced degradation study 
Stress degradation study using acid and alkali hydrolysis, chemical oxidation and dry heat 
degradation was carried out and interference of the degradation products were 
investigated. LRN and PCM were weighed (25 mg each) and transferred to two separate 
25 ml volumetric flasks and diluted up to the mark with mobile phase. These stock 
solutions were used for forced degradation studies. 
Forced degradation in basic media was performed by taking 2.5 ml stock solutions of LRN 
and PCM (1000 μg/ml) in two different 25 ml volumetric flasks and 5 ml of 1 N NaOH was 
added. Similarly, 2.5 ml aliquots of stock solutions of LRN and PCM were taken in same 
25 ml volumetric flask and 5 ml 1 N NaOH was added. All the flasks were stored at room 
temperature for 24 hrs. Solutions were neutralized with acid using pH meter and suitably 
diluted with mobile phase to obtain final concentration of 10 μg/ ml of PCM and LRN 
separately and in the mixture. Similarly, forced degradation in acidic medium was 
performed using 1 N HCl. 
To perform oxidative stress degradation, appropriate aliquots of stock solutions of LRN 
and PCM (1000 μg/ml) were taken in two different 25 ml volumetric flasks and 5 ml of 3% 
hydrogen peroxide was added. Similarly, appropriate aliquots of stock solutions of PCM 
and LRN were taken in same 25 ml volumetric flaks and 5 ml 3% hydrogen peroxide was 
added. All the mixtures were stored at room temperature for 24 hrs. Solutions were diluted 
with mobile phase to obtain final concentration of 10 μg/ ml of PCM and LRN separately 
and in mixture.  
To study dry heat degradation, solid drugs were exposed in oven at 80 ° for 2 h. After 2 h 
of heating 25 mg each of LRN and PCM were weighed and transferred to two separate 
volumetric flasks (25 ml) and diluted up to the mark with the mobile phase. Solutions were 
further diluted by taking appropriate aliquots in different 10 ml volumetric flasks to obtain 
final concentration of 10 μg/ml of LRN and PCM.  
All the reaction solutions were injected in the liquid chromatographic system and 
chromatograms were recorded. 
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